A Network Meta-Analysis of Two Doses of Recombinant Human Thrombopoietin for Treating Sepsis-Related Thrombocytopenia

Figure 5

Network meta-analysis of the relative efficacy (a) and the rank probabilities (b) among different treatment strategies in terms of the length of ICU stay. NAT, no additional treatment; IVIG, intravenous immunoglobulin; rhTPO 300, 300 U/kg/d recombinant human thrombopoietin; rhTPO 15000, 15000 U/d recombinant human thrombopoietin.

(a)

(b)